GlassScriptPhysician profile
Lori L Grant
NPI 1578645925
$11,265.87
in general payments reported to CMS, 2019-2025
44 companies · $3,711 in 2025
The $3,711 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $18.89 · 2023: $2,525 · 2024: $4,886 · 2025: $3,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,322 · Travel and Lodging: $1,700 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,322.41 |
| Travel and Lodging | $1,699.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $2,025.02 | 2025 | Senza |
| Boston Scientific Corporation | $1,494.53 | 2024 | Vercise |
| Pfizer INC. | $942.86 | 2023-2025 | |
| Abbvie INC. | $623.11 | 2023-2025 | |
| Genentech USA, INC. | $576.65 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Curonix LLC | $524.79 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Neurelis, INC. | $453.89 | 2023-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $444.01 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $388.68 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $335.75 | 2023-2024 | Rexulti |
| Lundbeck LLC | $324.68 | 2023-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $300.98 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $247.39 | 2024-2025 | Zeposia, Cobenfy |
| Sk Life Science, INC. | $240.32 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $230.08 | 2023-2024 | Nuplazid |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $187.88 | 2023-2025 | Qutenza |
| Harmony Biosciences LLC | $185.68 | 2023-2024 | Wakix |
| Emd Serono, INC. | $167.32 | 2023-2024 | Mavenclad |
| Amgen INC. | $161.56 | 2025 | Evenity, Prolia |
| Ucb, INC. | $148.57 | 2023-2024 | Nayzilam, Briviact |
| Celgene Corporation | $137.47 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2021 | |
| Idorsia Pharmaceuticals US INC | $123.90 | 2024 | Quviviq |
| Lilly USA, LLC | $102.99 | 2023-2024 | Amyvid, Emgality, Reyvow |
| Octapharma USA, INC. | $100.00 | 2023-2024 | Panzyga |
| Janssen Biotech, INC. | $99.99 | 2025 | |
| Axsome Therapeutics, INC. | $71.41 | 2024-2025 | Sunosi, Symbravo |
| Impel Pharmaceuticals INC. | $47.98 | 2023 | Trudhesa |
| Acorda Therapeutics, INC | $47.51 | 2024 | Inbrija |
| Azurity Pharmaceuticals, INC. | $45.15 | 2023-2024 | Horizant, Horizant |
| Takeda Pharmaceuticals U.S.A., INC. | $42.52 | 2023-2024 | Hyqvia, Gammagard |
| Mdd US Operations, LLC | $41.12 | 2024 | Gocovri |
| Merck Sharp & Dohme LLC | $41.08 | 2023 | Belsomra |
| Inspire Medical Systems, INC. | $38.45 | 2023 | Inspire |
| Merz Pharmaceuticals, LLC | $31.54 | 2024 | Xeomin, Ampyra |
| Vertex Pharmaceuticals Incorporated | $26.60 | 2025 | |
| Eisai INC. | $23.79 | 2024 | |
| Csl Behring | $22.51 | 2024 | Hizentra |
| Collegium Pharmaceutical, INC. | $19.09 | 2025 | Belbuca |
| Cranial Technologies, INC | $18.89 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $16.36 | 2023 | Spritam |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.13 | 2025 | Relistor |
| Amneal Pharmaceuticals LLC | $13.84 | 2024 | Rytary |
| Valinor Pharma, LLC | $9.81 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.